Table 1.

Normalisation of iodide efflux to processed CFTR protein

CFTR variant	Percentage processeda	Normalised processingb (%)	Normalised iodide effluxc (% peak response)	Iodide efflux to processed proteind (%)
Forskolin and genistein
WT	92 ± 2	100	100 ± 11	—
G550E	93 ± 4	101	150 ± 11e	149
4RK	85 ± 6	92	111 ± 9e	121
G551D	86 ± 8	93	51 ± 7	55
G550E-G551D	85 ± 8	92	111 ± 13	121
4RK-G551D	91 ± 5	99	119 ± 14	120
Forskolin and IBMX
WT	92 ± 2	100	100 ± 7	—
G550E	93 ± 4	101	ND	ND
4RK	85 ± 6	92	ND	ND
G551D	86 ± 8	93	15 ± 2	16
G550E-G551D	85 ± 8	92	17 ± 2	18
4RK-G551D	91 ± 5	99	37 ± 3	37

CFTR-mediated iodide efflux was evoked by treating BHK cells expressing CFTR variants with forskolin (10 μm) and either genistein (50 μm) or IBMX (100 μm). ND, not determined.

^aPercentage of CFTR protein processing given by [band C/(band B + band C) × 100].

^bRatio of ‘Percentage processed’ value for each CFTR variant to the equivalent value for WT-CFTR.

^cCFTR-mediated iodide efflux expressed as % of maximum response relative to that of WT-CFTR.

^dRatio of ‘Normalised iodide efflux’ value to the corresponding ‘Normalised processing’ value for a given CFTR variant.

^eData are from Roxo-Rosa et al. (2006).